Spots Global Cancer Trial Database for A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
Official Title: A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes
Study ID: NCT00260065
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Birmingham, Alabama, United States
, Phoenix, Arizona, United States
, Boca Raton, Florida, United States
, Fort Myers, Florida, United States
, Jacksonville, Florida, United States
, New Port Richey, Florida, United States
, Griffin, Georgia, United States
, Chicago, Illinois, United States
, Maywood, Illinois, United States
, Rochester, Minnesota, United States
, Hackensack, New Jersey, United States
, Buffalo, New York, United States
, Canton, Ohio, United States
, Charleston, South Carolina, United States
, Memphis, Tennessee, United States
, Houston, Texas, United States
, Midland, Texas, United States
, Seattle, Washington, United States
, La Crosse, Wisconsin, United States
, Milwaukee, Wisconsin, United States
, Toronto, Ontario, Canada
Contact Details
Name: Eisai US Medical Services
Affiliation: Eisai Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
